Moderna has opened its new vaccine manufacturing and R&D facility in Oxfordshire, UK, the Moderna Innovation and Technology ...

Sanofi has committed an additional $625m to its venture capital arm, Sanofi Ventures, bringing its total assets under ...

Biogen's Spinraza is not the first drug to face a CMC-related rejection recently, as SMA competitor drug, apitegromab, also ...

Daiichi Sankyo and AstraZeneca have received priority review from the US Food and Drug Administration (FDA) for Enhertu plus ...

Data at ECTRIMS will help back fenebrutinib as a potential addition to Roche’s arsenal of drugs, and help cement Ocrevus’s ...

The API facility, which will make orforglipron amongst other small molecules, is part of Eli Lilly’s $27bn US manufacturing ...

There’s been another detour in tolebrutinib’s path to market, with developer Sanofi revealing that the US Food and Drug ...

The European Commission (EC) has sanctioned the use of Servier’s Voranigo (vorasidenib) to treat certain brain tumours ...

As Eli Lilly and Novo Nordisk await approval of their oral GLP-1RAs, the healthcare editorial team discuss data and market opportunity.

Lilly plans to invest $6.5bn in an active pharmaceutical ingredients (API) manufacturing facility at Generation Park in ...

Tylenol’s label change plus leucovorin's approval offer a taster to the Trump administration’s plans to crack down on the US ...

While only two therapies have so far gained approval, the broader pipeline paints a picture of strong research and ...